MTVA
MTVA
NASDAQ · Biotechnology

Metavia Inc

$1.49
+0.03 (+2.05%)
As of Aug 14, 10:26 PM ET ·
Analyst Consensus
Strong Buy
8
Analysts
Moderate
Coverage
Buy 7 88%
Hold 1 13%
Sell 0 0%
Price Target
Analyst Price Target +433.6% upside
Low Target $5.82
Average Target $7.95
High Target $9.13
Current Price $1.49
Current
$1.49
Target
$7.95
$5.82 $7.95 avg $9.13
Scenario Analysis
Bear Case
$5.82
290.6%
Low target
Base Case
$7.95
+433.6%
Avg target
Bull Case
$9.13
+512.8%
High target
Risk/Reward
1.8x
Balanced
Price in Context
52-Week High
$19.03
-92.2% from high
52-Week Low
$0.97
+54.2% from low
Target vs 52W High
$7.95
-58.2% vs high
Next Earnings Report
Aug 18, 2026
2d
until earnings
EPS Est: $-0.84
Earnings in 2 days. Analyst targets may shift significantly after the report.
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Strong Buy 38 82% $257.58 +3.3%
AMGN
Amgen Inc
Hold 43 49% $190.87 -54.0%
GILD
Gilead Sciences Inc
Strong Buy 37 81% $362.68 +162.1%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 37 81% $438.34 -13.3%
REGN
Regeneron Pharmaceuticals
Buy 37 70% $76.80 -90.4%
NTRA
Natera Inc
Strong Buy 30 87% $142.91 -53.9%
RVMD
Revolution Medicines Inc
Strong Buy 28 93% $114.11 -44.0%
BIIB
Biogen Inc
Buy 43 67% $91.45 -56.4%